<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697511</url>
  </required_header>
  <id_info>
    <org_study_id>MS200527_0063</org_study_id>
    <secondary_id>2020-003668-13</secondary_id>
    <nct_id>NCT04697511</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants</brief_title>
  <official_title>A Phase I, Single-Sequence, Open-Label, Single- and Multiple-Dose Study of the Effect of Evobrutinib on Midazolam Pharmacokinetics in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effect of single dose and multiple doses of M2951 on midazolam&#xD;
      Pharmacokinetics (PK) in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Actual">February 25, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events (TEAEs) by Severity</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change From Baseline in Laboratory Parameters, Vital Signs and 12-Lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Number of participants with clinically significant change from baseline in laboratory parameters, vital signs and 12- lead ECG findings will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (tmax) of Midazolam and 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of Midazolam and 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of Midazolam and 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of Midazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Midazolam</measure>
    <time_frame>Pre-dose through 24 hours postdose on Days 1, 3 and 13</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Midazolam and/or M2951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.</description>
    <arm_group_label>Midazolam and/or M2951</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2951</intervention_name>
    <description>Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.</description>
    <arm_group_label>Midazolam and/or M2951</arm_group_label>
    <other_name>MSC2364447C</other_name>
    <other_name>Evobrutinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants are overtly healthy as determined by medical evaluation, including no&#xD;
             clinically significant abnormality identified on physical examination or laboratory&#xD;
             evaluation and no active clinically significant disorder, condition, infection or&#xD;
             disease that would pose a risk to participant safety or interfere with the study&#xD;
             evaluation, procedures, or completion&#xD;
&#xD;
          -  Participants have a body weight within 50.0 and 100.0 kilograms [kg] (inclusive) and&#xD;
             body mass index within the range of 19.0 and 30.0 kilograms per square meter [kg/m^2]&#xD;
             (inclusive)&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically relevant respiratory, gastrointestinal, renal,&#xD;
             hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric,&#xD;
             musculoskeletal, genitourinary, immunological, dermatological, connective tissue&#xD;
             diseases or disorders, as determined by medical evaluation&#xD;
&#xD;
          -  Individuals with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin&#xD;
             deficiency, or any other chronic liver disease including Gilbert's disease will be&#xD;
             excluded from the study&#xD;
&#xD;
          -  Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery&#xD;
             within 6 months prior to Screening&#xD;
&#xD;
          -  History of any malignancy&#xD;
&#xD;
          -  History of chronic or recurrent acute infection or any bacterial, viral, parasitic or&#xD;
             fungal infections within 30 days prior to Screening and at any time between Screening&#xD;
             and admission, or hospitalization due to infection within 6 months prior to Screening&#xD;
&#xD;
          -  History of shingles within 12 months prior to Screening&#xD;
&#xD;
          -  History of drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity&#xD;
             to the active drug substance and/or formulation ingredients; history of serious&#xD;
             allergic reactions leading to hospitalization or any other hypersensitivity reaction&#xD;
             in general, which may affect the safety of the participant and/or outcome of the study&#xD;
             per the Investigator's discretion&#xD;
&#xD;
          -  History of alcoholism or drug abuse within 2 years prior to Screening, or positive for&#xD;
             drugs of abuse, nicotine/cotinine or alcohol by the laboratory assays conducted during&#xD;
             Screening and Day -1&#xD;
&#xD;
          -  History of residential exposure to tuberculosis, or a positive QuantiFERON® test&#xD;
             within 4 weeks prior to or at the time of Screening&#xD;
&#xD;
          -  Administration of live vaccines or live-attenuated virus vaccines within 3 months&#xD;
             prior to Screening&#xD;
&#xD;
          -  Moderate or strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A&#xD;
             (CYP3A4/5) within 4 weeks prior to the first administration of study intervention&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200527_0063</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Midazolam</keyword>
  <keyword>Cytochrome P450</keyword>
  <keyword>Autoimmune disorders</keyword>
  <keyword>Inflammatory disorders</keyword>
  <keyword>Sedative-hypnotic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

